The pharmaceutical industry has traditionally viewed drug discovery and clinical development as separate stages of the R&D ...

AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...

Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...

Paradromics has announced a new collaboration with Siemens Healthineers to construct an advanced multimodal imaging platform ...

As Washington ramps up efforts to tighten cross-border life sciences deals involving Chinese assets, Beijing is moving to ...

The fourth Riyadh Global Medical Biotechnology Summit (RGMBS) closed on September 16 with 46 agreements signed. Disclosed ...

When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition ...

Frazier Life Sciences also hit the Nasdaq on Friday with its second biotech-focused special purpose acquisition company (SPAC ...

Estuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical ...

Iambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development ...

Verdiva Bio has scrapped a phase 2 trial of its once-weekly oral GLP-1 drug candidate VRB-101. | Verdiva Bio has scrapped a ...

Looking to expand its oncology portfolio, Gilead Sciences has tapped Vir Biotechnology’s masked T-cell engager (TCE) tech in ...